Table of Contents Table of Contents
Previous Page  660-661 / 1726 Next Page
Information
Show Menu
Previous Page 660-661 / 1726 Next Page
Page Background

Stage I-II HIR factors

Stage I-II serous / cc

R

Pelvic RT

3x carboplatin

+ paclitaxel + VBT

Completed accrual 2012

N=601, primary endpoint PFS

89% underwent lymphadenectomy

15% serous, 5% clear cell, 74% stage I

First GOG#249 results

McMeekin, SGO 2014, Fleming, IGCS 2014; Randall ASTRO 2017

Update, median FU 53 months

No difference RFS and Overall Survival